Kornimate/medical-research-clean huggingface dataset:
understanding health services delivery for fibromyalgia

Conditions: Fibromyalgia; Fibromyalgia, Primary; Fibromyalgia, Secondary

Summary: this research study aims to: i) explore and understand how health and social care for people with fibromyalgia living in the uk is organised and delivered. ii) identify models of practice to inform co-design of new care pathways for people with fibromyalgia living in the uk. to do this, up to ten uk-based case studies will be conducted in total: at least one each in england, scotland and wales. interviews will be conducted with approximately 10 participants per case study, for a total of 100 participant interviews. qualitative observations (in-person or on-line) will be conducted with a similar number of people (total 100 participants). online focus groups will also be carried out with approximately 6 to 8 participants per group (up to ten groups for a total 60-80 participants). participants will include healthcare professionals (for example, doctors, nurses, allied health professionals), social care practitioners (for example, social prescribers), service delivery managers, commissioners and other individuals involved in the organisation and delivery of health and social care services for people with fibromyalgia living in the uk.


Eligibility criteria:
inclusion criteria: * nhs and/or non-nhs organisations in the uk providing health and social care to people with fibromyalgia. * health and social care professionals identifying and or providing support for people with fibromyalgia in one of the ten case studies. * nhs/non-nhs staff influential in the organisation and/or delivery of health and social care to people with fibromyalgia in one of the ten case studies, for example, service managers, professional service leads, commissioners. exclusion criteria: * nhs/non-nhs organisations in the uk not providing health or social care to people with fibromyalgia. * nhs/non-nhs staff who are not able to communicate sufficiently well in english to participate effectively.
shouldice hospital outcome study

Conditions: Inguinal Hernia

Summary: a prospective cohort study recruiting participants from the shouldice hospital. the study population consists of healthy patients electing to receive hernia surgery for a primary inguinal hernia on an inpatient basis. the goal of this study is to determine the incidence of hernia pain and its intensity as well as other related outcomes up to one year after primary unilateral inguinal hernia repair.


Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form. * willing to comply with all study procedures and be available for the duration of the study (patients have fixed address, access to phone, email, internet, and/or a computer) * male or female, aged 18 to 90 years. * subjects having surgery on a primary unilateral inguinal hernia * in good general health as evidenced by medical history * capable of speaking and reading english sufficiently well to complete the questionnaires exclusion criteria: * surgery is deemed an emergency procedure (any obstruction, incarceration or irreducible hernias). * other abdominal hernias being operated on at the same time or surgery is planned during the follow-up period (incisional and umbilical hernias) * if hernia recurs within the study period and there is a reoperation within the year * bmi \>40kg/m2 * patients unable to understand english, written and spoken * patients with collagen or connective tissue disorders * local (site of surgery) or systemic infection * any known diseases that impair nerve function * patients who end up getting a mesh repair during surgery * impairment of cognitive function (e.g. dementia) * pregnancy or lactation * anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
effect of palonosetron on remifentanil for preventing emergence cough in female

Conditions: Gallbladder Diseases

Summary: the primary purpose of this study is to investigate the optimal ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female patients who receive the palonosetron or not.

remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. it allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. in addition, cough suppression of remifentanil enables smooth extubation with reduced complications. however, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. reduced ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.

Eligibility criteria:
inclusion criteria: * laparoscopic cholecystectomy under general anesthesia exclusion criteria: * bmi \> 30 kg/m2, respiratory infection, uncontrolled hypertension
short message system (sms) for caregivers of suicidal patients to prevent recidivism of suicide attempts

Conditions: Prevention of the Suicide

Summary: assessment of the feasibility of a monitoring device by sms in which messages are sent by the caregiver after a suicidal act.


Eligibility criteria:
inclusion criteria: * male or female, over 18 years of age and hospitalized; * survivor of a suicide attempt; * giving informed, dated and signed consent; * can be reached by mobile phone. the study is proposed to all adult suicides and to the patient's designated caregiver, meeting the inclusion criteria. exclusion criteria: * patient whose clinical condition is incompatible with the formulation of his non-opposition. * the patient and his / her caregiver shall not be afforded a protective justice measure.

Keywords: suicide attempt sms monitoring phone prevention control tertiary healthcare
assessment of pain of pelvic congestion syndrome treated by coils embolization

Conditions: Pelvic Pain

Summary: summary: main objective: to evaluate the efficacy of pelvic gonadal vein embolization with coils in treatment of pelvic congestion syndrome methods: retrospective study included 25 patients in the university hospital of brest. the primary outcome measure: to evaluate (to measure) pain relief using visual analogous scale (vas) before and after gonadal vein embolization for pelvic congestion syndrome the secondary outcome measures were to assess the impact of the treatment on specific and general symptoms through a survey.

a retrospective, non-invasive monocentric study of our hospital 10-year registry (including data on mri angiography and vascular doppler ultrasound) of patients who have already undergone coil embolization of pelvic gonadal vein in treatment of pelvic congestion syndrome. these patients will be contacted by phone to participate in the study. an information letter will be handed out and the study protocol will be explained to the patients. after obtaining their written consent, they will be asked to fill out the study's validated questionnaire at home and return it to us through pre-paid regular mail. a face to face interview with the patient will be scheduled to assess the correlation between patient's clinical symptoms and survey results. there will be no change in patient's routine follow-up care. all physician investigators of the study are experts in their field of medicine (e.g. interventional mri angiography, vascular disease).

Eligibility criteria:
inclusion criteria: * clinical symptoms of pelvic congestion syndrome documented by vascular doppler ultrasound and vascular dynamic mri * failed medical treatment. * \> 18 years \< 60 years old exclusion criteria: * \< 18 years old * under legal guardian * asymptomatic pelvic congestion syndrome * psychiatric disorder * endometriosis. * chronic pelvic disease * pregnancy * neoplasia * acute intermittent porphyria

Keywords: syndrome pain pelvic vein embolization
the incidence and treatment of insulin resistance among men with erectile dysfunction

Conditions: Erectile Dysfunction; Metabolic Syndrome; Insulin Resistance

Summary: determine if men with erectile dysfunction (ed) are more likely to have insulin resistance compared to healthy controls.

insulin is a hormone produced by the body that lets sugar into the cells, where it is used for energy. insulin resistance occurs when the body's cells have a decreased ability to react to insulin. this leads to an increase in insulin secretion. over time, insulin resistance can lead to higher levels of sugar in the blood (diabetes), and can also contribute to obesity, high blood pressure, high cholesterol levels and heart disease. there are no simple tests to actually diagnose insulin resistance. currently, the glucose tolerance test is used to diagnose ir, but it involves several blood draws over a 2-hour period. another purpose of this study is to compare a blood test involving only one blood draw to the 2-hour glucose tolerance test, which involves several blood draws over a 2-hour period. it is well known that diabetes often leads to erectile dysfunction. because insulin resistance occurs before diabetes, it is possible that erectile dysfunction may occur in some individuals while they have insulin resistance, but before they develop diabetes. if this is true, it might be possible to use erectile dysfunction as a sign of insulin resistance, which may lead to more timely treatment of insulin resistance and may delay or prevent the development of diabetes, and the other problems mentioned above.

Eligibility criteria:
inclusion criteria: * 18-65 years of age, male, exclusion criteria: * diabetes, peyronies

Keywords: erectile dysfunction metabolic syndrome insulin resistance etiology
treatment of refractory (acute or chronic) graft-versus-host disease by the infusion of expanded in-vitro allogenic mesenchymal stem cell

Conditions: Graft-vs-Host Disease (GVHD)

Summary: clinical trial based on the use of a new therapeutic strategy (msc infusion) for the treatment of patients who have developed a gvhd refractory to the usual therapeutic measures after undergoing an allogenic hematopoietic stem cell transplant.

this is a multicenter, single dose study of allogenic mesenchymal stem cell (1-2 x 10\^6 msc/kg recipient´s bodyweight). msc will be infused, by a central venous catheter, to patients diagnosed with gvhd refractory to first-line or subsequent treatment. all patients will receive the same treatment. msc suspension will be obtained from the bone marrow aspiration of a family donor and expanded in-vitro in a specific culture medium with autologous donor´s serum and with no animal-derived products.

Eligibility criteria:
inclusion criteria: * patients with hematological malignancies who had been undergone an allogenic hematopoietic stem cell transplant and diagnosed with gvhd refractory to a usual treatment. * adequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process. * adequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease. * patients with ages between 18 and 65 years. * signature of informed consent form is required to be done by patient and donor. exclusion criteria: * patients whose hematopathology has not been controlled by the transplant or is in progress. * patients with bacterial, viral or fungal infection not being controlled with the adequate treatment. * patients with an inadequate cardiac or pulmonary function. * patients who, in the investigator´s point of view, are not in situation to tolerate the treatment. * patients who do not have the required donor (hla-identical sibling donor and not hla-identical sibling donor). * pregnant females or childbearing potential who are not on adequate contraceptive measures. * patients \ 65 years. * patients who do not sign the informed consent.

Keywords: graft-vs-host disease (gvhd) mesenchymal stem cell (msc) allogeneic hematopoietic stem cell transplant allotransplant allogenic refractory csm/eich2005
comparison of 5% potassium hydroxide with 10% potassium hydroxide solution in treatment of molluscum contagiosum

Conditions: Molluscum Contagiosum

Summary: molluscum is a virus-related skin infestation which is commonly seen among children. molluscipox virus, the largest human virus, causes it. mc typically manifests as a single or multiple dome-shaped, shiny, pearly white papules with a central dimple. in immunocompetent individuals, spontaneous resolution usually occurs within 18 months; however, the lesion may persist for several years. asymptomatic lesions are common. it is also linked to a high risk of transmission and an increasing prevalence in global populations1-2. patients may receive therapy for social and cosmetic reasons, and also to avoid spreading disease to others. numerous modalities are currently available, including potassium hydroxide, curettage, cryotherapy, disinfected needle pricking, photodynamic therapy, laser, salicylic acid, glycolic acid etc3-4. potassium hydroxide (koh) is a topical treatment for molluscum contagiosum. dermatologists routinely use potassium hydroxide (koh) in varying concentrations to identify fungal elements. because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of mc. because it is inexpensive and widely accessible, it has the potential to be a useful method for treating for mc in resource-constrained countries5-6. the purpose of this study is to examine two varied concentrations of potassium hydroxide (5%-koh vs 10%-koh) among mc patients in order to determine the most effective koh concentration to manage molluscum contagiosum among children.


Eligibility criteria:
inclusion criteria \<100 lesions no therapy within the earlier one month exclusion criteria: known hypersensitivity and immunodeficiency

Keywords: potassium hydroxide 5% and 10% lotion
3d printed bolus in post-mastectomy radiotherapy

Conditions: Breast Neoplasms; Radiotherapy Side Effect

Summary: recently, there is growing interest in the application of three-dimensional (3d) printed bolus to radiotherapy.at present, the researches on the application of 3d-printed bolus in breast cancer are mainly focused on air gap between skin and bolus or electron beam conformal therapy \[7,15\], there are no clinical experience with customized 3d-printed bolus for volumetric modulated arc therapy (vmat) in daily practice has been published up to now. we aim to evaluate dosimetry and application of 3d-printed bolus for the post-mastectomy radiotherapy (pmrt) with volumetric modulated arc therapy (vmat). seventy five patients with breast cancer receiving radiotherapy following post-mastectomy in our department were randomly selected in this study. the accuracy of fit of the 3d-printed bolus to the chest wall was improved significantly relative to conventional bolus.this study demonstrates customized 3d-printed bolus in post-mastectomy radiation therapy improves fit of the bolus compared to conventional bolus. furthermore, vmat based on 3d-printed bolus significantly improves the chest wall target coverage and the conformity of plan, and reduces the dose of ipsilateral lung and heart, compared to conventional bolus.


Eligibility criteria:
inclusion criteria: * breast cancer patients with post-mastectomy treatment exclusion criteria: * na
can a very high result from a screening test for celiac disease be used to diagnose celiac disease?

Conditions: Celiac Disease

Summary: this study is to see if a high response to the ttg screening test for celiac disease is as accurate as the current method of diagnosing celiac disease which entails a general anesthetic and upper endoscopy to obtain biopsies of the small intestine. if the screening blood test is highly accurate, then some patients that are being evaluated for celiac disease may not require an upper gi endoscopy and can be treated more quickly. if they respond to the therapy then they will be deemed to have celiac disease.

all patients scheduled for upper gi endoscopy will be approached for recruitment into the study. a minimum of 4 small intestinal biopsies will be taken from all subjects and controls. all ttg specimens will be run through the hospital laboratory. intermediate level ttg values 20-100 will be assessed separately and as part of the larger group. an optional part b of the study will assess the frequency of lactose intolerance in subjects prior to the start of a gluten free diet.

Eligibility criteria:
inclusion criteria: inclusion-all patients planned to undergo upper gi endoscopy with biopsies. exclusion criteria: exclusion-refusal to participate, not planning to have biopsies performed with the endoscopy.

Keywords: ttg pediatric comparison study
glucocorticoid receptor blockade with mifepristone in patients with mild adrenal hypercortisolism

Conditions: Mild Hypercortisolism

Summary: the purpose of this study is to determine whether mifepristone is an effective treatment for hyperglycemia due to mild hypercortisolism. * to test the hypothesis that gr blockade with mifepristone will decrease the severity of metabolic syndrome features as measured by waist circumference, lipid profile, body mass index, blood pressure and insulin resistance, measured by homa-ir score. * to test the hypothesis that gr blockade with mifepristone will improve qol, depression and anxiety scores, measured by validated assessments, in patients with mild hypercortisolism.


Eligibility criteria:
inclusion criteria: * \>18 years of age * incidentally noted adrenal nodule \<4 cm with benign imaging characteristics * evidence of mild hypercortisolism * evidence of diabetes or abnormal glucose tolerance exclusion criteria: * contraindication to mifepristone * indication for unilateral adrenalectomy * evidence of other adrenal hormone hypersecretion * lactating mothers * women of childbearing age unwilling to use an effective, nonhormonal form of contraception

Keywords: mild hypercortisolism subclinical cushing's syndrome preclinical cushing's syndrome
personalized follow-up program in the type 2 diabetes prevention

Conditions: Type2 Diabetes

Summary: in france, the global prevalence of diabetes was estimated to 5% of the population in 2016, the type two diabetes (dt2) corresponding to 90% of cases. this number is widely underestimated because most people are untreated and undiagnosed. due to the silent character of this disease, it is estimated that 20 à 30 % of diabetic adults have not yet been diagnosed. the conclusions, presented during the annual meeting of easd in 2019, suggest that the precursor signs of this disease could be present until 20 years before the diagnosis. diabetes is a metabolic disease and people are diagnosed, in general, around 40-50 years old. the main risk factor of type ii diabetes is lifestyle (rich diet, sedentary) but there is also other factors like hyperlipidemia, high blood pressure, high fasting blood sugar, stress, smoking, heredity, family history of diabetes, or gestational diabetes. this induces an increase of obesity, itself a major risk factor for type ii diabetes occurrence. from an economical aspect, chronic pathologies (including diabetes) represent 60% of health insurance expenses, even though it concerns 35% of insured persons, i.e. 20 million of patients. the average of annual reimbursement for a type 2 diabetic patient is 4890 euros. in this context, this study is the first step of thinking about a different, coordinated care approach, based on a preventive rather than curative approach.

this study includes a personalized care program, including the patient follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months. the nurse will review the patient's progress and provide advice and contact with professionals: physical activity, psychologists, dieticians, endocrinologists, etc the main objective of this study is to compare, after 5 years of follow-up, the risk factors associated with type 2 diabetes, between participants who received personalized follow-up and those who did not. the secondary objectives are to compare the occurrence of type 2 diabetes, the quality of life and the compliance to the program between participants who received personalized follow-up and those who did not.

Eligibility criteria:
inclusion criteria: * person with a findrisc score ≥ 10 points * person who has given his/her express written and informed consent exclusion criteria: - person already diagnosed with a type 2 diabetes

Keywords: diabetes metabolic diseases endocrine system diseases prevention
comparison of the ganglionated plexi activity in patients with different forms of atrial fibrillation guided by sumo technology

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to compare dua (discrete uptake accumulations) of mibg activity in patients with different forms of atrial fibrillation and within a sub-group of healthy subjects.


Eligibility criteria:
inclusion criteria: 1. male or female patients, age ≥ 18 and ≤ 80 years. 2. male or female, age ≥ 50 years in the healthy volunteers group 3. no heart pathology (for volunteers) 4. paf, pers af and l-s pers af (ecg documented). 5. lvef ≥ 50% 6. able to provide written informed consent 7. able to comply with the requirements of the study exclusion criteria: 1. previous af ablation therapy 2. clinical evidence of active coronary ischemia, significant valvular heart disease, or hemodynamically significant congenital cardiac abnormality 3. recent (3 months) myocardial infarction (mi), stroke or transient ischemic attack (except if the patient had a des implanted stent post-mi it would be one year) 4. contra-indication to iodine-123 meta-iodobenzylguanidine (123i-mibg), iodine, isoproterenol 5. use of medication for non-cardiac medical conditions that is known to interfere with 123i-mibg uptake and cannot be safely withheld for at least 24 hours prior to the d-spect study procedures
outcomes data of adipose stem cells to treat chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (svf), has on the quality of life of people with chronic obstructive pulmonary disease (copd). svf contains multiple cellular components, including stem cells, with both regenerative and anti-inflammatory properties. this therapy has shown promise for ameliorating the symptoms of copd. this study is designed to evaluate quality of life changes in individuals with copd for up to 12 months following svf treatment.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with chronic obstructive pulmonary disease (copd) * subjects scheduled for a stem cell/svf treatment * subjects willing and able to sign informed consent * subjects willing and able to perform follow-up interviews and surveys exclusion criteria: * subjects with additional major health condition/disease diagnoses * subjects that are pregnant or breastfeeding